A Phase I/II Study of Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells
Patients with Multiple myeloma who have undergone non-myeloablative allogeneic stem cell transplant will receive 6 vaccinations of donor derived dendritic cells combined with specific protein produced by multiple myeloma.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : Idiotype-pulsed allogeneic dendritic cells
Phase: Phase 1/Phase 2
Ages Eligible For Study:
1. For specimen collection and idiotype protein development: - Must be secretory myeloma with at least .5g/dl serum IgG protein - Clinically stage 2 or 3 multiple myeloma - Karnofsky performance status of 70 or greater 2. For Vaccination: - Eligible patients must have completed tandem autologous and nonmyeloablative allogeneic transplant for multiple myeloma at Stanford University Medical Center with stable disease or complete response to prevaccine therapy - Karnofsky performance status of 70 or greater. - ALT and AST must be <2X upper limit of normal. Total bilirubin < 1.5X upper limit of normal. - Serum creatinine <1.5X upper limit of normal. - Hemoglobin >9g/dl - Patients must be HIV negative. - Patients must provide signed, informed consent Donor Inclusion Criteria (allo donor is the same donor used for non-myeloablative transplant) - Age >17 years - HIV negative - Must provide signed, informed consent